Futuremeds Spain S.L. — Clinical Trial Site

49 Registered trials

34 Currently recruiting

Organisation

Futuremeds Spain S.L.

Location

Madrid, Spain

Identifier

ORG-100050324

Address

Glorieta De Mejico 1, 41012, Spain

Departments

#11102: Neurology
#40857: Medicina Interna
#724003:Neurología
#724007:Neurología
604: Reumatología
72405 Medicina Interna
72406 Medicina Interna
72407 Medicina Interna
Allergy
Cardiologia
Cardiology
Deparment
Department
Departmet
Dept. of Rheumatology
Dermatology
Family Medicine
FutureMeds Spain Madrid
FutureMeds Spain Sevilla
Gastroenterology
Internal Medicine
Medicina de familia
Medicina Familia
Medicina Interna
N/A
Neumologia
Neuropediatric
Oncology
Pneumology
Reumatologia
Rheumatology
Servicio de Cardiologia
Servicio de Neurología

Clinical trials at this site (49)

Search interface

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Recruiting

2024-513959-33-00 Asthma 4 2025-05-13
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting

2023-508191-11-00 Systemic lupus erythematosus (SLE) 5 2024-11-28
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO… Recruiting

2023-508760-29-00 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) 5 2024-10-21
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease Ended

2025-521791-63-00 Moderately to Severely Active Rheumatologic Disease 4 2025-12-18
A Phase 3 Study to Assess the Safety and Immunogenicity of High-dose Influenza Vaccine in Adults ≥ 60 years of Age Ended

2024-519743-15-00 Influenza immunisation 5 2025-10-20
MULTICENTER, RANDOMIZED, BLIND AND CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY IN THE CORRECTION OF DEFICIT IN SUBJECTS WI… Ended

2024-514528-17-00 Severe vitamin D deficiency 6 2025-09-15
A Phase 2b Study to Assess IMVT-1402 in Participants with Cutaneous Lupus Erythematosus Ended

2024-516745-39-00 Cutaneous lupus erythematosus 4 2025-07-11
A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended

2024-518321-15-00 Asthma 4 2025-05-30
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513208-32-00 Chronic Spontaneous Urticaria 5 2024-12-16
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510341-19-00 acne vulgaris 5 2024-11-14
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510339-12-00 acne vulgaris 5 2024-11-11
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus Ended

2024-510584-37-00 Systemic Lupus Erythematosus 4 2024-10-22
A Phase 2a/b study of the efficacy and safety of subcutaneous amlitelimab in adults with non-responsive celiac disease Ended

2024-511213-38-00 Coeliac disease 4 2024-10-15
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No… Ended

2023-510279-80-00 Prurigo nodularis 4 2024-09-25
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended

2022-503004-24-00 Influenza virus 5 2023-10-20
A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended

2023-506368-14-00 Systemic lupus erythematosus (SLE) 5 2021-09-07
A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended

2023-503910-60-00 Rheumatoid arthritis 4 2024-03-05